Luxturna cleared for sale in Europe, but payer support uncertain

Spark Therapeutics has secured marketing authorization from the European Commission for its gene therapy Luxturna, OK'd for a rare inherited type of blindness. The thumbs up makes Luxturna the first gene therapy approved for a genetic disease in both the U.S. and Europe.